orkshop

Scientific Programme
orkshop
Scientific Coordinators
A. d’Arminio Monforte (Milan, I)
C.F. Perno (Rome, I)
M. Puoti (Milan, I)
Inflammation and chronic
hepatitis/HIV infections:
who is the driver?
Milan, Italy Palazzo delle Stelline
January 30-31, 2014
orkshop
Inflammation and chronic
hepatitis/HIV infections:
who is the driver?
Endorsements
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
■
Honorary President
Ministero della Salute
Istituto Superiore di Sanità
Agenzia Italiana del Farmaco
Regione Lombardia
Provincia di Milano
Comune di Milano
Università degli Studi, Milan
Dipartimento di Scienze della Salute, Università degli
Studi, Milan
Università degli Studi Tor Vergata, Rome
Azienda Ospedaliera San Paolo - Polo Universitario, Milan
Azienda Ospedaliera Niguarda Ca' Granda, Milan
Fondazione Policlinico Tor Vergata, Rome
SIV, Società Italiana di Virologia
SIVIM, Società Italiana di Virologia Medica
AISF, Associazione Italiana per lo Studio del Fegato
AMCLI, Associazione Microbiologi Clinici Italiani
Fondazione AVIRALIA
Fondazione ICONA
ANLAIDS, Associazione Nazionale per la lotta contro l'AIDS
LILA, Lega Italiana per la lotta contro l'AIDS
Associazione NADIR
NPS Italia, Network Persone Sieropositive
Mauro Moroni Professor Emeritus, University of Milan I
Scientific Coordinators
Antonella d’Arminio Monforte San Paolo Hospital,
University of Milan I
Carlo Federico Perno University of Tor Vergata, Rome I
Massimo Puoti Niguarda Ca’ Granda Hospital, Milan I
Scientific Committee
Massimo Andreoni University of Tor Vergata, Rome I
Mario Angelico University of Tor Vergata, Rome I
Andrea Antinori IRCCS - INMI Lazzaro Spallanzani, Rome I
Savino Bruno Fatebenefratelli Hospital, University Milan
Bicocca, Milan I
Mario Clerici Don C. Gnocchi Foundation, University of Milan I
Massimo Colombo Foundation IRCCS Maggiore Hospital,
University of Milan I
Andrea Cossarizza University of Modena and Reggio
Emilia, Modena I
Andrea De Maria University of Genoa, IRCCS AOU San
Martino - IST Genoa I
Massimo Galli Luigi Sacco Hospital, University of Milan I
Andrea Gori San Gerardo Hospital, Monza I
Adriano Lazzarin University Vita-Salute San Raffaele, Milan I
Alberto Mantovani Humanitas Clinical Institute, University
of Milan I
Giuliano Rizzardini Luigi Sacco Hospital, University of Milan I
Mario Strazzabosco University Milan Bicocca, Milan I
Massimo Zuin San Paolo Hospital, University of Milan I
Scientific Secretariat
Giulia Marchetti San Paolo Hospital, University of Milan I
Roberto Rossotti Niguarda Ca’ Granda Hospital, Milan I
Valentina Svicher University of Tor Vergata, Rome I
2
Faculty
Massimo Andreoni University of Tor Vergata, Rome I
Gioacchino Angarano University Hospital of Bari I
Mario Angelico University of Tor Vergata, Rome I
Andrea Antinori IRCCS - INMI Lazzaro Spallanzani,
Rome I
Guido Antonelli University Hospital Umberto I and Sapienza
University, Rome I
Alessandra Bandera San Gerardo Hospital, Monza I
Raffaele Bruno University of Pavia I
Savino Bruno Fatebenefratelli Hospital, University Milan
Bicocca, Milan I
Giampiero Carosi Professor Emeritus, University of
Brescia I
Antonella Castagna San Raffaele Scientific Institute, Milan I
Francesca Ceccherini-Silberstein University of Tor
Vergata, Rome I
Antonella Cingolani Catholic University, Rome I
Mario Clerici Don C. Gnocchi Foundation, University of
Milan I
Massimo Colombo Foundation IRCCS Maggiore Hospital,
University of Milan I
Antonio Craxì Paolo Giaccone Hospital, Palermo I
Antonella d’Arminio Monforte San Paolo Hospital,
University of Milan I
Gabriella d’Ettorre University Hospital Umberto I, Rome I
Andrea De Luca Siena University Hospital, Siena I
Andrea De Maria University of Genoa, IRCCS AOU San
Martino - IST Genoa I
Daniel C. Douek Vaccine Research Center, National Institute
of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda USA
Carlo Ferrari University Hospital of Parma I
Giovanni Battista Gaeta Second University of Naples I
Massimo Galli Luigi Sacco Hospital, University of Milan I
Antonio Gasbarrini Catholic University, Gemelli Hospital,
Rome I
Nicola Gianotti San Raffaele Scientific Institute, Milan I
Enrico Girardi IRCCS - INMI Lazzaro Spallanzani, Rome I
Andrea Gori San Gerardo Hospital, Monza I
Peter Hunt University of California, San Francisco USA
Giuseppe Ippolito IRCCS - INMI Lazzaro Spallanzani,
Rome I
Christine Katlama University Pierre et Marie Curie, PitiéSalpétrière Hospital, Paris F
Alan L. Landay Rush University, Chicago USA
Adriano Lazzarin University Vita-Salute San Raffaele, Milan I
Michael M. Lederman Case Western Reserve University
School of Medicine, University Hospitals/Case Medical
Center, Cleveland USA
Massimo Levrero Sapienza University, Rome I
Miriam Lichtner Sapienza University of Rome, Polo Pontino,
Latina I
Alberto Mantovani Humanitas Clinical Institute, University
of Milan I
Giulia Marchetti San Paolo Hospital, University of Milan I
Fabio Marra University of Florence I
Claudio Maria Mastroianni Sapienza University of Rome,
Polo Pontino, Latina I
Gabriele Missale University Hospital of Parma I
Mario Umberto Mondelli University of Pavia, Foundation
IRCCS San Matteo General Hospital, Pavia I
Mauro Moroni Professor Emeritus, University of Milan I
Carlo Federico Perno University of Tor Vergata, Rome I
Massimo Pinzani Institute for Liver and Digestive Health,
University College London, Royal Free Hospital, London UK
Massimo Puoti Niguarda Ca’ Granda Hospital, Milan I
Giovanni Raimondo University Hospital of Messina I
Agostino Riva Luigi Sacco Hospital, University of Milan I
Giuliano Rizzardini Luigi Sacco Hospital, University of Milan I
Jürgen Rockstroh University of Bonn D
Roberto Rossotti Niguarda Ca’ Granda Hospital, Milan I
Christine Rouzioux Necker Hospital, University Paris
Descartes, Paris F
Stefano Rusconi Luigi Sacco Hospital, University of Milan I
Caroline Sabin University College London UK
Andrea Savarino Istituto Superiore di Sanità, Rome I
Guido Silvestri Emory University School of Medicine,
Yerkes National Primate Research Center, Atlanta USA
Mario Strazzabosco University Milan Bicocca, Milan I
Valentina Svicher University of Tor Vergata, Rome I
Gloria Taliani Sapienza University, Rome I
Giuseppe Tambussi San Raffaele Scientific Institute, Milan I
Luca Valenti Foundation IRCCS Ca’ Granda General
Hospital, University of Milan I
3
orkshop
Inflammation and chronic
hepatitis/HIV infections:
who is the driver?
Scientific Programme January 30, 2014
10.30-10.45
10.45-11.00
11.00-11.45
11.00-11.30
11.30-11.45
11.45-13.00
Welcome Addresses
Rationale and presentation of the Workshop
M. Moroni
A. d’Arminio Monforte, C.F. Perno, M. Puoti
OPENING LECTURE
Conveners M. Andreoni, L. Valenti
Inflammation and chronic viral infections
Discussion
SESSION 1 What is the role of inflammation in the different
scenarios of persistent hepatitis virus infections
12.45-13.00
Conveners M. Clerici, V. Svicher
Role of the cell-mediated immune response in liver
damage and viral persistence in HBV infection
Q&A
HCV and the host inflammatory response
Q&A
HBV and HCV in the setting of HIV-related immune impairment
Q&A
Discussion
13.00-14.00
Lunch and poster discussion
14.00-15.15
SESSION 2 HIV vs inflammation: who drives what
11.45-12.00
12.00-12.05
12.05-12.20
12.20-12.25
12.25-12.40
12.40-12.45
15.00-15.15
Conveners A. Gori, G. Marchetti
HIV and inflammation: what can we learn from animal models?
Q&A
Viral replication as driver of inflammation?
Q&A
Inflammation as driver of viral replication?
Q&A
Discussion
15.15-16.00
LECTURE
15.15-15.45
15.45-16.00
Conveners G. Carosi, G.B. Gaeta
Pathogenesis of liver fibrosis in the setting of chronic hepatitis C
Discussion
16.00-16.15
Coffee break
14.00-14.15
14.15-14.20
14.20-14.35
14.35-14.40
14.40-14.55
14.55-15.00
A. Mantovani
A. De Maria
4
C. Ferrari
M.U. Mondelli
R. Bruno
S. Bruno
G. Silvestri
P. Hunt
A.L. Landay
A. Savarino
M. Pinzani
M. Angelico
January 30, 2014
16.15-17.15
SESSION 3 Oral presentations based on selected abstracts
Conveners G. Marchetti, R. Rossotti, V. Svicher
Discussants A. Bandera, S. Rusconi
HIV-Envelope Protein Gp120 Actives the Nalp3-Inflammasome Through the Engagement of
CCR5 Receptor in Human Hepatic Stellate Cells
A. Cappon*, R. Bruno**, S. Gessani***, A. Masotti°, and F. Marra
*University of Florence, Florence, Italy, **IRCCS, University of Pavia, Pavia, Italy, ***Istituto Superiore di Sanità,
Rome, Italy, °Ospedale Pediatrico Bambino Gesù, Rome, Italy
Strong antiviral activity of thiazolides against HIV-1BaL infection in vitro
F. Gnudi*, M. Biasin*, D. Trabattoni*, M. De Luca*, S.V. Ibba*, I. Saulle*, M. Fiocchi*, J.F. Rossignol**,
M. Clerici*
*Chair of Immunology, University of Milan, Italy, **The Glycobiology Institute, Department of Biochemistry, University
of Oxford, UK
IFN and bacterial TLR ligands act synergistically to increase production of CXCL10 from
hepatocytes
M. Crane*,**, S. Tennakoon*,**, B. Sebolao*,**, D. Iser*,**,***, S.R. Lewin*,**
*Alfred Hospital, Monash University, Melbourne, Australia **Burnet Institute, Melbourne, Australia ***St Vincent’s
Hospital, Melbourne, Australia
Monocyte and Dendritic cell subsets, inflammatory and fibrotic soluble markers in HCV
monoinfected and HCV/HIV coinfected subjects: the effect of anti-HCV therapy
M. Lichtner*, S. Savinelli**, C. Mascia**, T. Tieghi*, R. Marocco*, P. Zuccalà**, A. Ermocida**, S. Vita°,
F. Mengoni**, G.M. Liuzzi***, T. Latronico***, C.M. Mastroianni*, V. Vullo**
*Infectious Diseases Unit, Sapienza University, Latina, **Public Health and Infectious Diseases, Sapienza University,
Rome, Italy ***Biosciences, Biotechnology and Biofarmaceutics, University of Bari, Bari °Sapienza University of
Rome, Cenci Bolognetti Foundation
Pharmacologically Induced Functional Cure-like Condition in Chronically SIVmac251-Infected
Macaques is Associated with Decreased Levels of Immune Activation in T-cells
I.L. Shytaj*, R. Pal**, M.G. Ferrari**, J. Livesay**, M.G. Lewis***, E. Garaci° and A. Savarino*
*Istituto Superiore di Sanità, Rome, Italy **ABL, Rockville, Maryland, USA ***BIOQUAL, Inc. Rockville, Maryland,
USA °Dept. of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
Inherent and HCV-dependent regulation of NK cell receptors: NKp30, DNAM-1, CD85j in
pegIFN -Ribavirin treated patients with diverging clinical courses
F. Bozzano*, A. Picciotto*, P. Costa*, F. Marras**, V. Fazio*, S. Marenco*, I. Hirsch***, D. Olive***,
L. Moretta**, A. De Maria*,°
*Università di Genova, Italy, **Istituto G. Gaslini, Genova, Italy, ***Institute Paoli Calmettes, IFR 137, INSERM, Marseilles,
France, °S.S. Infettivologia, IRCCS San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
17.15-18.10
SESSION 4 Microbial translocation and inflammation
17.55-18.10
Conveners M. Galli, M. Strazzabosco
Inhibition of inflammation during acute SIV infection
Q&A
Microbial translocation and inflammation in HBV- and HCV- mediated cirrhosis
Q&A
Discussion
18.10-18.55
LECTURE
18.10-18.40
Convener G. Angarano
Clinical and immunological correlates of spontaneous control of HIV infection
Discussion
17.15-17.30
17.30-17.35
17.35-17.50
17.50-17.55
18.40-18.55
5
D.C. Douek
A. Gasbarrini
G. Tambussi
C. Katlama
N. Gianotti
orkshop
Inflammation and chronic
hepatitis/HIV infections:
who is the driver?
Scientific Programme January 31, 2014
09.00-10.35
SESSION 5 Immune activation and clinical outcome:
what role and what clinical marker
10.20-10.35
Conveners A. Lazzarin, G. Missale
Drivers and outcomes of inflammation in HIV infection
Q&A
Markers of inflammation and fibrosis in the clinics: HCV and HBV
Q&A
How to track HIV reservoirs in the clinics?
Q&A
How to track hidden virus in the clinics: HCV and HBV
Q&A
Discussion
10.35-10.50
Coffee break
10.50-12.25
SESSION 6 Interplay between immune activation/inflammation and
clinical progression of HIV-, HBV- and HCV- related diseases:
what space for therapy interventions
09.00-09.15
09.15-09.20
09.20-09.35
09.35-09.40
09.40-09.55
09.55-10.00
10.00-10.15
10.15-10.20
M.M. Lederman
F. Marra
C. Rouzioux
G. Taliani
F. Ceccherini-Silberstein
12.10-12.25
Conveners C.M. Mastroianni, G. Rizzardini
Control of inflammation: is cART enough?
Q&A
Is control of inflammation sufficient in the prevention
of HBV- related disease?
Q&A
Control of HIV: which impact does it have on liver disease
progression in hepatitis coinfection?
Q&A
Does HCV eradication halt inflammation
and affect fibrosis in chronic hepatitis C?
Q&A
Discussion
12.25-13.25
SESSION 7 Oral presentations based on selected abstracts
10.50-11.05
11.05-11.10
11.10-11.25
11.25-11.30
11.30-11.45
11.45-11.50
11.50-12.05
12.05-12.10
A. Antinori
G. Raimondo
J. Rockstroh
A. Craxì
A. Castagna
Conveners G. d’Ettorre, E. Girardi, M. Lichtner
Discussants A. Cingolani, A. Riva
Targeting Gut Mucosa in HIV+ Subjects With Prebiotics and Glutamine: A Clinical Trial
S. Serrano-Villar1, J. Vázquez2, N. Madrid1, A. Vallejo1, J. Martínez-Botas3, T. Sainz4, M. Vera5,
C. Rodríguez5, J. Del Romero5, S. Ferrando-Martínez6, F. Dronda1, M. Coronel1, E. Domínguez1,
A. Latorre2, M.J. Gosalbes2, A. Moya2, S. Moreno1, V. Estrada6, Laboratory of Immunovirology,
Biomedicine Institute of Seville (IBIS), Service of Infectious Diseases, University Hospital Virgen
6
January 31, 2014
del Rocío, Sevilla 7, HIV Unit, Department of Internal Medicine, University Hospital Clínico San
Carlos, 28040 Madrid, Spain
1Hospital Universitario Ramón y Cajal, Madrid, 2Centro Superior de Investigación en Salud Pública, Valencia, y
CIBEResp, Instituto de Salud Carlos III, Madrid, 3Hospital Universitario Ramón y Cajal, Madrid y CIBEResp, Instituto
de Salud Carlos III, Madrid, 4Hospital Universitario Gregorio Marañón, 5Centro Sandoval, Madrid, 6Hospital Virgen
del Rocío, Sevilla, 7Hospital Universitario Clínico San Carlos, Madrid
Bone Marrow CD34+ Progenitors Cells Harbor HIV Genomes and HIV-DNA is Correlated to
Plasma HIV-RNA
V. Bordoni, I. Abbate, D. Viola, G. Rozera, M. Bibas, A. Ammassari, C. Agrati, A. Rinaldi, M.
Capobianchi, F. Martini
National Institute for Infectious Diseases "L. Spallanzani", IRCCS, Rome Italy
sEPCR as Inflammatory Biomarker in Naïves Chronic HIV-Infected Patients after the
beginning of Anti-Retroviral Therapy
S. Chiappetta*, M. Ripa*, M. Pogliaghi*, V. Longo**, C. Razzari***, P. Cinque**, E. Faioni***, S. Nozza**,
A. Lazzarin**, G. Tambussi**
*Università Vita- Salute San Raffaele, Milan, Italy; **San Raffaele Scientific Institute, Milan, Italy; ***Università degli
Studi di Milano, Milan, Italy
CD8+CD28-CD127loCFD39+ Treg: a new biomarker for HIV disease progression?
A. Parodi*, C. Dentone**, F. Kalli*, A. Di Biagio***, P. Fraccaro*, G. Orofino°, G. Cenderello°°, M.
Giacomini*, D. Fenoglio* and G. Filaci*
*University of Genoa, Genoa, Italy, **Sanremo Hospital, Sanremo, Italy, ***IRCSS AOU San Martino Hospital-IST,
Genoa, Italy, °Amedeo di Savoia Hospital, Turin, Italy, °°Galliera Hospital, Genoa, Italy
Chronic inflammation in a long term cohort of HIV infected patients according to the
normalization of CD4:CD8 ratio under ART
G. Bruno*, A. Saracino*, L. Scudeller**, A. Volpe*, G. Punzi*, A. Lagioia*, N. Ladisa*, L. Monno*, G.
Angarano*
*Clinic of Infectious Diseases, University of Bari **IRCCS San Matteo, Pavia, Italy
cART Intensification Results in Better Anti-HCV Treatment Response in HCV/HIV Co-infected
Patients
A. Uglietti, A. De Bona, M. Cerrone, E. Merlini, G. Marchetti and A. d’Arminio Monforte
San Paolo Hospital, Milan, Italy
13.25-14.10
Lunch and poster discussion
14.10-15.25
SESSION 8 The role of drugs in preventing cancer
14.10-14.25
14.25-14.30
14.30-14.45
14.45-14.50
14.50-15.05
15.05-15.10
15.10-15.25
15.25-15.40
15.40-16.10
Conveners G. Antonelli, G. Ippolito
Targeting the inflammation by virus eradication in the prevention
of HCV associated hepatocellular carcinoma
Q&A
Interplay between HBV and inflammatory host factors
in the pathway towards liver cancer
Q&A
Impact of ART in non-AIDS related cancers
Q&A
Discussion
Awards Ceremony
Closing remarks
M. Colombo
M. Levrero
C. Sabin
A. De Luca
G. Antonelli, G. Marchetti, R. Rossotti, V. Svicher
A. d’Arminio Monforte, C.F. Perno, M. Puoti
7
Optimizing treatment in HIV
1
1. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1; Luglio 2012
http://www.salute.gov.it/imgs/C_17_pubblicazioni_1301_allegato.pdf
Selected Posters
1. Innate immunity cell activation in virologically suppressed HIV infected Maraviroc treated patients
C. Dentone1,2, A. Di Biagio3, A. Parodi2, F. Bozzano4, P. Fraccaro5, A. Signori6, G. Cenderello7, G. Orofino8,
M. Guerra9, G. Ferrea1, C. Viscoli3,10, M. Giacomini2,5, A. De Maria2,10, G. Filaci2,11, D. Fenoglio2,11
1Sanremo Hospital, Center of Excellence for Biomedical Research (CEBR), 2University of Genoa, 3IRCCS San Martino Hospital,
Genoa, DIMES Dept of Experimental Medicine, 4University of Genoa, Department of Informatics, Bioengineering, Robotic and
System Engineering (DIBRIS), 5University of Genoa, Dept of Health Sciences (DISSAL)-Section of Biostatistics, 6University of
Genoa, 7Galliera Hospital, Genoa, 8Amedeo di Savoia Hospital,Turin, 9La Spezia Hospital, 10DISSAL University of Genoa, 11Dept
of Internal Medicine (DIMI), University of Genoa
2. Asymptomatic HIV Patients: Dysfunctions on Biochemical and Immunological Tests, According to
Different Therapeutic Responses
K.I. Tasca*, M. Gatto*, C.C. Camargo*, A.A. Tanikaw a*, J.E. Corrente*, F.H. Aoki**, L.R. Souza*
*Botucatu Medical School, Univ Estadual Paulista (UNESP), Botucatu, Brazil; **University of Campinas (UNICAMP), Campinas, Brazil
3. Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection
I. Saulle*, M. Biasin*, M. Sironi**, R. Cagliani**, F. Gnudi*, S. Ibba*, G. Filippi***, S. Yahyaei*, C. Tresoldi**,
S. Riva**, D. Trabattoni*, L. De Gioia***, S. Lo Caputo°, F. Mazzotta°, D. Forni*, C. Pontremoli*, J.A. Pineda°°,
U. Pozzoli**, A. Rivero-Juarez°°°, A. Caruz^, M. Clerici^^-^^^
*Scientific Institute IRCCS E. MEDEA, Bioinformatics, Bosisio Parini, Italy; **Department of Biomedical and Clinical Sciences,
University of Milan, Milan, Italy; ***Department of Biotechnology and Biosciences, University of Milan-Bicocca, Milan, Italy; °S. Maria
Annunziata Hospital, Florence, Italy; °°Infectious Diseases and Microbiology Clinical Unit. Valme Hospital, Seville, Spain; °°°Maimonides
Institut for Biomedical Research (IMIBIC)-Reina Sofia Universitary Hospital-University of Cordoba, Spain; ^Immunogenetics Unit,
Department of Experimental Biology, University of Jaen, Jaen, Spain; ^^Chair of Immunology, Department of Physiopathology and
Transplantation, University of Milan, Milan, Italy; ^^^Don C. Gnocchi Foundation ONLUS, IRCCS, Milan, Italy
4. Does HIV-1 Co-receptor Tropism correlate with fibrosis progression in HIV/HCV co-infected patients?
G. Bruno, A. Saracino, L. Scudeller, G. Punzi, A. Lagioia, N. Ladisa, L. Monno and G. Angarano
Clinic of Infectious Diseases, University of Bari; Scientific Direction, Clinical Epidemiology Unit, IRCCS San Matteo Foundation,
Pavia, Italy
5. Effects of Dietary Supplementation with Probiotics in HIV-1 Infected Patients
N. Giustini, S. Serafino, S. Marcellini, E. Nelson Cavallari, V. Bellelli, P. Vittozzi, T. Ascoli Bartoli, S. Gebremeskel,
L. Bianchi, G. Ceccarelli, G. d’Ettorre, V. Vullo
"Sapienza" University of Rome, Italy
6. Is Residual Viremia a Trigger of Immune Activation in HIV-1 Infected Subjects?
S. Serafino, N. Giustini, F. Falasca, P. Maida, V. Bellelli, F. Tierno, L. Bianchi, G. Ceccarelli, O. Turriziani,
G. d’Ettorre, G. Antonelli, V. Vullo
"Sapienza" University of Rome, Italy
7. Non-cirrhotic Portal Hypertension in three HIV-seropositive Women: when Ultrasound Matters
M.T. Giordani*, V. Manfrin*, E. Brunetti**, D. Danieli***, F. Rinaldi**
*Infectious and Tropical Diseases Unit, San Bortolo Hospital, Vicenza, Italy, **Department of Infectious Diseases, San Matteo
Hospital Foundation, University of Pavia, Pavia, Italy, ***Pathology Service, San Bortolo Hospital, Vicenza, Italy
8. Moderate physical activity improves soluble and cell markers of inflammation in cART-treated patients
V. Longo*, M. Bonato**, L. Galli*, S. Bossolasco*, G. Pavei**, L. Passeri*, G. Merati**, A. Lazzarin*, A. La Torre**,
P. Cinque*
*San Raffaele Scientific Institute, Milano, ITALY **Università degli Studi di Milano, Milano, Italy
9. Anti-HCV Treatment-Associated T Cell Subsets Changes in HIV-HCV Coinfected Patients on Effective HAART
A. De Bona*, A. Uglietti*, M. Cerrone*, F. Bai*, G. Carpani**, E. Senigaglia**, G. Marchetti*, A. d’Arminio Monforte*
*Clinic of Infectious Diseases, San Paolo Hospital-University of Milan, Italy **Transfusional Center, San Paolo Hospital- University
of Milan, Italy
9
General information
orkshop
Inflammation and chronic
hepatitis/HIV infections:
who is the driver?
Congress web site
www.inflammation2014.com
Workshop Venue
Palazzo delle Stelline
Corso Magenta, 61 - 20123 Milan, Italy
www.stelline.it
CME Provider and Organizing Secretariat
Effetti srl
Via Gallarate, 106 - 20151 Milan, Italy
Ph. +39 02 3343281 - Fax +39 02 33496370 - [email protected]
Official language
English. No simultaneous translation provided
CME accreditation
The Workshop has obtained 7 CME credits (ID number 150-77648) from Italian Health Ministry for the following professionals:
Medical Doctor, Biologist, Territory and Hospital Pharmacist, Nurse, Medical Laboratory Technician and Psychologist. Medical
specialties include: Infectious and Tropical Diseases, Hygiene, Epidemiology and Public Health, Microbiology and Virology, Allergology
and Clinical Immunology, Internal Medicine and Gastroenterology. Credits will be given only if a participant attends 100% of the
teaching event and provides correct answers to at least 75% of the questions included in the final assessment questionnaire.
Participants are also required to wear the identification badge during working sessions, to provide their signature for attendance
tracking purposes and to complete the satisfaction questionnaire.
Poster session
Authors may post up their posters subject to registration. The selected posters should be affixed in the foyer outside Sala Volta (1st
floor), one hour before the beginning of the Workshop and taken away at the end of the scientific works. Posters should be prepared
in English. During poster discussion, authors are kindly requested to remain at disposal near their own poster for discussion or questions
to be asked by conference participants.
Cyber point
A Cyber point is available at exhibition area in the foyer outside Sala Volta (1st floor).
Slide center
A slide center will be available to speakers, with computers, CD writer, printer and technical support. Only Powerpoint slide
presentations will be accepted. If a special equipment is needed, this should be communicated in advance to the Organizing Secretariat.
Slides must be submitted 2 hours before the scheduled presentation.
Technical equipment
Congress room is suitable for Powerpoint presentations and equipped with computers and overhead projectors. Speakers may not
use their own computers for their presentations.
Exhibition area
A technical-pharmaceutical and scientific publishing exhibition area will be open from Thursday January 30th at 10:30 a.m. to Friday
January 31st at 04:30 p.m.
Web repository
Abstracts (oral and poster) and slide presentations of any authors who provide its consent to publication will be published on Workshop
web site (www.inflammation2014.com) at the end of the event.
Congress Abstracts
Scan the Qr-code image with your mobile device or visit
www.inflammation2014.com/abstract/ to reach Workshop Abstracts
11
The Chairmen, the Scientific Secretariat and the Provider wish to thank
for support given in the form of unrestricted educational grants
and the following Companies:
PLATINUM SPONSOR
GOLD SPONSORS
OTHER SPONSORS
Supported by Gilead Sciences Europe Ltd who provided funding. Gilead Sciences Europe Ltd has
had no input into the content of the materials and presentations used at this event.

Download Report